

---

UNITED STATES  
SECURITIES AND EXCHANGE COMMISSION  
WASHINGTON, D.C. 20549

**FORM 8-K**

CURRENT REPORT

PURSUANT TO SECTION 13 OR 15(d) OF  
THE SECURITIES EXCHANGE ACT OF 1934

Date of Report: June 16, 2008  
(Date of earliest event reported)

**LECTEC CORPORATION**

(Exact name of registrant as specified in its charter)

Commission File Number: 0-16159

---

**Minnesota**  
(State or other jurisdiction of incorporation)

**41-1301878**  
(IRS Employer Identification No.)

**5610 Lincoln Drive, Edina, Minnesota 55436**  
(Address of principal executive offices, including zip code)

**(952) 933-2291**  
(Registrant's telephone number, including area code)

**Not Applicable**  
(Former name or former address, if changed since last report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

- Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
  - Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
  - Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
  - Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
- 
-

**Item 7.01 Regulation FD Disclosure.**

The Annual Meeting of Shareholders (“Annual Meeting”) of LecTec Corporation (“LecTec”) will be held at 3:00 p.m., Central time, on June 19, 2008 in Eden Prairie, Minnesota. Attached as Exhibit 99.1, and incorporated herein by reference, is a copy of the slide presentation for the Annual Meeting. At the Annual Meeting the Rader, Fishman & Grauer PLLC law firm will be making a presentation regarding its capabilities. Attached as Exhibit 99.2, and incorporated herein by reference, is a copy of LecTec’s press release dated June 16, 2008 announcing the engagement of Rader, Fishman & Grauer PLLC to represent LecTec in connection with its patent portfolio.

**Item 9.01 Financial Statements and Exhibits.**

(d) Exhibits.

- 99.1 Slides presented during the LecTec Corporation Annual Meeting of Shareholders held on June 19, 2008.
- 99.2 Press release issued by LecTec Corporation on June 16, 2008.

**SIGNATURE**

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

LECTEC CORPORATION

By: /s/ Judd A. Berlin

Judd A. Berlin

Chief Executive Officer and Chief Financial Officer

Date: June 19, 2008

## EXHIBIT INDEX

<b>Exhibit Number</b>	<b>Description</b>
99.1	Slides presented during the LecTec Corporation Annual Meeting of Shareholders held on June 19, 2008.
99.2	Press release issued by LecTec Corporation on June 16, 2008.

Annual Shareholder Meeting



*June 19, 2008*

---

---

## AGENDA

- Overview – Judd Berlin, CEO
- Financial Update – Bill Johnson, Controller
- Rader, Fishman and Grauer PLLC Law Firm – Thomas E. Bejin
- Q&A
- Business Portion of the Meeting / Wrap-Up

## COMPANY OVERVIEW

- Previously contract manufacturer of topical patches.
- Sold electrode and hydrogel assets in 2000.
- Ceased manufacturing operations in 2004.
- Currently an intellectual property licensing and holding company.

## ASSETS IN THE BUSINESS

- Cash of approximately \$800,000 (March 08).
- Intellectual Property Portfolio.
- A Royalty-Generating License Agreement with Novartis.
- A Net Operating Loss Carry-forward.
- A publicly-traded entity.



## INTELLECTUAL PROPERTY PORTFOLIO

- Issued Patents - 18 U.S. and 42 International.
- Applications Pending – 4 U.S. and 2 International.
- Patents cover a wide range of indications.
- Two new patent applications cover:
  - Child-Proof/Pet-Proof
  - Hand Sanitizing Patch
- Duration of critical patents is 5-15 years.
- Patents cover a wide range of indications.
- Most important patents relate to Hydrogel Transdermal Drug Delivery Technology.

## '263 PATENT RE-EXAMINATION PROCESS

- In December 2000 the Company undertook a process to have its flagship patent based on its hydrogel technology re-examined.
- The purpose of the re-examination was to expand its claims related to the patent.
- The re-examination process took a substantial amount of time due to their thorough review of all past and added new claims.
- While the Company believed competitors were infringing on this patent, it was precluded from taking any enforcement action while the patent was in re-examination.
- In April 2007 the Company received a re-examination certificate expanding its claims.

## PATENT ENFORCEMENT

- The Company believes several parties have infringed on its intellectual property.
- Engaging a respected law firm that would represent us in these matters took considerable time and effort.
- As mentioned earlier, we are pleased to have engaged Rader, Fishman last Monday (June 16) to represent us in connection with our Intellectual Property.

## NOVARTIS LICENSING AGREEMENT

- Supply and Licensing Agreement in 2004.
- Supply portion ended in late 2004.
- Novartis has exclusive license for Vapor Patches for life of patent (approximately 5.5 years). Then, perpetual paid-up license.
- Novartis obligated to pay royalty starting January 2005.
- In June 2006, Novartis had a nationwide recall on its Triaminic vapor patch products due to accidental ingestion.
- To address recall, introduced patch with aversive agent.
- Novartis is back on the market and has introduced an adult patch as well in July 2007.

## SUMMARY

- Continue to support Novartis Agreement and look for other similar opportunities.
- Protect and capitalize on our Intellectual Property Portfolio.
- Explore opportunities to capitalize on the other assets of the business.

**LECTEC CORPORATION**  
**COMPARATIVE BALANCE SHEETS**

*Financial Overview – Bill Johnson*

	<b>UNAUDITED</b> <b>3/31/2008</b>	<b>2007</b>	<b>2006</b>	<b>2005</b>
CASH & TEMP INVESTMENTS	\$ 808,877	\$ 832,925	\$ 1,281,785	\$ 1,310,578
NOVARTIS RECEIVABLE	23,929	100,431	-	214,906
PREPAID INSURANCE AND DEPOSITS	<u>55,666</u>	<u>62,877</u>	<u>66,285</u>	<u>66,735</u>
TOTAL CURRENT ASSETS	888,472	996,233	1,348,070	1,592,219
OTHER ASSETS - PATENTS	46,969	42,918	65,191	90,651
DIRECTOR AND OFFICER INSURANCE	<u>50,698</u>	<u>60,838</u>	<u>101,396</u>	<u>141,955</u>
	<u>97,667</u>	<u>103,756</u>	<u>166,587</u>	<u>232,606</u>
TOTAL ASSETS	<u>\$ 986,159</u>	<u>\$ 1,099,989</u>	<u>\$ 1,514,657</u>	<u>\$ 1,824,825</u>
ACCOUNTS PAYABLE - TRADE	\$ 57,733	\$ 13,407	\$ 14,479	\$ 10,495
ACCRUED EXP. - RESERVE FOR SALES RETURNS	130,000	130,000	130,000	98,350
ACCRUED EXP. - OTHER	<u>59,313</u>	<u>57,767</u>	<u>73,395</u>	<u>52,015</u>
TOTAL CURRENT LIABILITIES	247,046	201,174	217,874	160,860
<b>CURRENT RATIO</b>	<b>3.60</b>	<b>4.95</b>	<b>6.19</b>	<b>9.90</b>
COMMON STOCK - PAR VALUE	42,900	41,760	41,490	41,490
ADDITIONAL CONTRIBUTED CAPITAL	12,197,138	12,198,278	11,847,536	11,847,536
ACCUMULATED DEFICIT	<u>(11,500,925)</u>	<u>(11,341,223)</u>	<u>(10,592,243)</u>	<u>(10,225,061)</u>
TOTAL STOCKHOLDERS' EQUITY	<u>739,113</u>	<u>898,815</u>	<u>1,296,783</u>	<u>1,663,965</u>
TOTAL LIAB & S/H EQUITY	<u>\$ 986,159</u>	<u>\$ 1,099,989</u>	<u>\$ 1,514,657</u>	<u>\$ 1,824,825</u>
BOOK VALUE PER SHARE	\$0.18	\$0.22	\$0.31	\$0.40



## STATEMENTS OF OPERATIONS

	UNAUDITED 3/31/08	2007	2006	2005
<b>CONTINUING OPERATIONS:</b>				
Revenue – royalty and licensing fees	\$ 21,029	\$ 100,431	\$ 126,660	\$ 443,352
Operating expenses	187,912	900,352	524,038	811,298
Loss from operations	<u>(166,883)</u>	<u>(799,921)</u>	<u>(397,378)</u>	<u>(367,946)</u>
Interest income	7,181	50,941	61,846	41,424
Net loss from continuing operations	<u>(159,702)</u>	<u>(748,980)</u>	<u>(335,532)</u>	<u>(326,522)</u>
<b>DISCONTINUED OPERATIONS:</b>				
Net loss from discontinued operations	<u>-</u>	<u>-</u>	<u>(31,650)</u>	<u>(204,090)</u>
<b>NET LOSS</b>	<u><b>(\$159,702)</b></u>	<u><b>(\$748,980)</b></u>	<u><b>(\$367,182)</b></u>	<u><b>(\$530,612)</b></u>
<b>WEIGHTED AVERAGE COMMON SHARES O/S:</b>				
Basic and diluted	4,227,401	4,165,724	4,148,998	4,134,232
<b>LOSS PER COMMON SHARE:</b>				
Basic and diluted -				
Continuing operations	\$ (0.04)	\$ (0.18)	\$ (0.08)	\$ (0.08)
Discontinued operations	<u>-</u>	<u>-</u>	<u>(0.01)</u>	<u>(0.05)</u>
Total	<u>\$ (0.04)</u>	<u>\$ (0.18)</u>	<u>\$ (0.09)</u>	<u>\$ (0.13)</u>

## STATEMENTS OF CASH FLOWS

Years ended December 31, 2007 and 2006

	<u>2007</u>	<u>2006</u>
Cash flows from operating activities:		
Net loss	\$ (748,980)	\$ (367,182)
Net loss from discontinued operations	-	<u>31,650</u>
Net loss from continuing operations	(748,980)	(335,532)
Adjustments to reconcile net loss from continuing operations to net cash used by operating activities:		
Stock compensation expense	332,925	-
Amortization of patent costs	22,273	25,460
Changes in operating assets and liabilities of continuing operations:		
Royalty receivable	(100,431)	214,906
Prepaid expenses and other	43,966	41,009
Accounts payable	(1,072)	3,984
Accrued expenses	<u>(15,628)</u>	<u>21,380</u>
Net cash used by operating activities from continuing operations	<u>(466,947)</u>	<u>(28,793)</u>
Cash flows from financing activity from continuing operations:		
Proceeds from the exercise of stock options	<u>18,087</u>	-
Net decrease in cash and cash equivalents	(448,860)	(28,793)
Cash and cash equivalents – beginning of year	<u>1,281,785</u>	<u>1,310,578</u>
Cash and cash equivalents – end of year	<u>\$ 832,925</u>	<u>\$ 1,281,785</u>



**LecTec Corporation**

5610 Lincoln Drive  
Edina, Minnesota 55436

Contact: Bill Johnson, Controller (952-933-2291 X24)

**LecTec Corporation Engages Patent Litigation Counsel**

**June 16, 2008 — Edina, MN — LecTec Corporation (OTCBB: LECT)** announced today that it has engaged the law firm of Rader, Fishman & Grauer PLLC to represent it in connection with its patent portfolio. Rader, Fishman & Grauer ranks as one of the top patent litigation firms in the US and has represented clients in more than three hundred federal court cases since 1996. Rader Fishman is recognized as a “go to” law firm by companies engaged in patent litigation. LecTec will be working with R. Terrance Rader, considered one of the country’s top patent litigators with over three decades of experience, along with Thomas E. Bejin and Glenn Forbis who each have in excess of fifteen years of patent trial experience. LecTec looks forward to working with the Rader Fishman firm. .

**About LecTec Corporation**

LecTec Corporation is an intellectual property licensing and holding company. The Company’s primary focus is to derive royalty and other income from patents that the Company owns based on its advanced skin interface technologies. The Company was an innovator in hydrogel-based topical delivery of therapeutic over-the-counter medications, which provide alternatives to topical creams and ointments. A hydrogel is a gel-like material having an affinity for water and similar compounds. These gels are ideal for delivering medication onto the skin. The Company holds multiple domestic and international patents on its hydrogel technology.

**Cautionary Statements**

This press release contains forward-looking statements concerning possible or anticipated future results of operations or business developments which are typically preceded by the words “believes,” “wants,” “expects,” “anticipates,” “intends,” “will,” “may,” “should,” or similar expressions. Such forward-looking statements are subject to risks and uncertainties, which could cause results or developments to differ materially from those, indicated in the forward-looking statements. Such risks and uncertainties include, but are not limited to, the Company’s dependence on royalty payments from Novartis Consumer Health, Inc. (“Novartis”), which recently began selling an adult vapor patch licensed by the Company, the Company’s dependence on key personnel and Board of Director members, the success or failure of any attempt by the Company to protect or enforce its patents and territories of coverage, the issuance of new accounting pronouncements, the availability of opportunities for licensing agreements related to patents that the Company holds, limitations on market expansion opportunities, and other risks and uncertainties detailed from time to time in the Company’s filings with the Securities and Exchange Commission, and particularly as described in the “Cautionary Statements” filed as Exhibit 99.01 to our Form 10-KSB for the year ended December 31, 2007.